NASDAQ · NVCT
Healthcare · Biotechnology
$23.99
Down-$0.41 (-1.69%)
Updated Sep 14, 2026, 3:27 PM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 19 trading sessions · Daily adjusted prices
NVCT closed at $23.99 after 19 trading sessions, up 25.73% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $22.96 | $24.24 | $22.28 | $23.99 | 221.08K |
| Sep 10, 2026 | $22.09 | $23.02 | $22.01 | $22.49 | 107.05K |
| Sep 9, 2026 | $23.89 | $24.5399 | $22.67 | $22.78 | 165.63K |
| Sep 8, 2026 | $24.00 | $24.6897 | $22.73 | $23.99 | 136.31K |
| Sep 4, 2026 | $24.00 | $25.19 | $23.96 | $24.49 | 117.17K |
| Sep 3, 2026 | $24.00 | $24.62 | $22.82 | $24.37 | 135.97K |
| Sep 2, 2026 | $23.06 | $24.01 | $23.06 | $23.92 | 188.61K |
| Sep 1, 2026 | $22.80 | $23.81 | $22.77 | $23.06 | 176.93K |
| Aug 31, 2026 | $23.52 | $24.35 | $22.57 | $22.73 | 192.57K |
| Aug 28, 2026 | $24.93 | $25.65 | $23.29 | $23.73 | 137.2K |
| Aug 27, 2026 | $25.03 | $25.84 | $24.35 | $25.19 | 319.9K |
| Aug 26, 2026 | $25.80 | $25.80 | $23.84 | $25.00 | 362.89K |
| Aug 25, 2026 | $23.90 | $25.9399 | $23.85 | $25.89 | 276.63K |
| Aug 24, 2026 | $23.56 | $24.55 | $23.335 | $23.87 | 231.13K |
| Aug 21, 2026 | $23.59 | $23.9299 | $22.83 | $23.56 | 196.98K |
| Aug 20, 2026 | $22.98 | $23.99 | $22.36 | $23.35 | 230.01K |
| Aug 19, 2026 | $21.44 | $23.74 | $21.00 | $23.33 | 362.93K |
| Aug 18, 2026 | $19.13 | $20.91 | $19.06 | $20.91 | 217.87K |
| Aug 17, 2026 | $18.85 | $19.32 | $18.51 | $19.08 | 102.6K |
The latest Smart Investors Daily articles mentioning NVCT.
NVCT research
Company profile and research snapshot.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 24, 2026 | Cantor Fitzgerald | Overweight | — |
| Jul 6, 2026 | Roth Capital | Buy | — |
| Jun 22, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 12, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 4, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Jun 30, 2026
Nuvectis intends to use the net proceeds from the offering to continue to advance the development programs of NXP100, NXP200, and NXP900 or any future product candidate, hiring of additional personnel, capital
Benzinga · Jun 29, 2026
Nuvectis Pharma, Inc. (NASDAQ:NVCT), a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions and oncology, today announced
Benzinga · Feb 13, 2026
-SEC Filing
Yahoo · Feb 11, 2026
FORT LEE, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the year ended December 31, 2025 and provided an update on recent business progress. Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, “20
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NVCT.
